{
  "slug": "bone-marrow-donor-complications",
  "question": "What are the odds of serious complications from donating bone marrow?",
  "category": "health",
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Bone marrow donation carries a disproportionate fear burden relative to its actual risk profile. The phrase \"bone marrow\" evokes images of long needles inserted into the hip, general anesthesia, and weeks of painful recovery — imagery that has persisted even as the majority of donations have shifted to peripheral blood stem cell (PBSC) collection, which involves no surgery at all. Surveys of potential registry joiners consistently identify fear of the procedure as the primary barrier to registration, ahead of time commitment or inconvenience. The perception is further inflated by dramatic anecdotes shared online and a general conflation of discomfort (which is common) with serious medical harm (which is rare).\n",
    "rough_estimate": "Many potential donors assume a significant risk of lasting harm or even death",
    "kind": "intuition"
  },
  "native": {
    "display": "~0.6% serious adverse events for PBSC donors; ~2.4% for marrow donors",
    "numerator": 6,
    "denominator": 1000,
    "unit": "per PBSC donation",
    "population": "unrelated NMDP donors, 2004-2009 cohort"
  },
  "normalized": {
    "lifetime_us_adult": 0.006,
    "display": "~1 in 170 chance of a serious adverse event per donation",
    "log_value": -2.22,
    "assumptions": "Uses the PBSC serious adverse event rate of 0.56% from the Halter et al. 2009 NMDP prospective trial as the baseline, since PBSC now accounts for the majority of unrelated donor collections. The figure represents the per-donation risk, not a cumulative lifetime probability, because most donors donate only once. Life-threatening events occur at roughly 1 in 1,000 donations. No fatalities were documented in the NMDP cohort.\n",
    "uncertainty": {
      "low": 0.003,
      "high": 0.024
    },
    "scope": "activity_specific_lifetime"
  },
  "sources": [
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2668845/",
      "title": "Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program",
      "publisher": "Bone Marrow Transplantation / Nature Publishing Group",
      "source_type": "primary_study",
      "statistic": "0.6% of 2,408 PBSC donors experienced serious adverse events; 6% experienced grade III-IV toxicities; no fatalities",
      "excerpt": "\"Serious and unexpected toxicities occurred in 0.6% of donors. Grade III-IV adverse events occurred in 6% of donors. No fatalities were observed in this prospective cohort of 2,408 unrelated PBSC donors.\"\n",
      "source_date": "2009-04-01",
      "source_accessed": "2026-04-18",
      "archive_url": "https://web.archive.org/web/20260426194118/https://pmc.ncbi.nlm.nih.gov/articles/PMC2668845/",
      "calculation_notes": "The 0.6% serious adverse event rate among PBSC donors is the central estimate. This prospective NMDP trial tracked 2,408 unrelated donors from filgrastim mobilization through collection and 1-year follow-up. Grade III-IV events (6%) include expected side effects of G-CSF such as bone pain and headache that resolve after collection. The 0.6% figure captures events that were both serious and unexpected — the threshold relevant to the fear question.\n"
    },
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4047500/",
      "title": "Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation",
      "publisher": "Blood / American Society of Hematology",
      "source_type": "peer_reviewed",
      "statistic": "SAE rate 0.56% for PBSC vs 2.38% for BM; life-threatening events 0.31% PBSC vs 0.99% BM; no donor deaths in NMDP cohort",
      "excerpt": "\"Bone marrow donors had a higher rate of serious adverse events at 2.38% compared to 0.56% for peripheral blood stem cell donors. Life-threatening, serious unexpected, or chronic/disabling events occurred in 0.99% of BM donors vs 0.31% of PBSC donors.\"\n",
      "source_date": "2014-06-05",
      "source_accessed": "2026-04-18",
      "archive_url": "https://web.archive.org/web/20260420032306/https://pmc.ncbi.nlm.nih.gov/articles/PMC4047500/",
      "calculation_notes": "This study compared SAE rates between BM and PBSC donation within the NMDP registry (donors 2004-2009). The threefold difference in life-threatening events (0.99% BM vs 0.31% PBSC) is clinically significant and explains the shift toward PBSC as the preferred collection method. No increased cancer risk was observed in long-term follow-up of PBSC donors, addressing a theoretical concern about filgrastim use.\n"
    },
    {
      "url": "https://www.nmdp.org/get-involved/join-the-registry/donate-pbsc/donor-requirements-faqs",
      "title": "Bone Marrow & Blood Stem Cell Donor FAQs",
      "publisher": "NMDP (formerly Be The Match)",
      "source_type": "reputable_reference",
      "statistic": "Fewer than 1% of PBSC donors experience serious side effects; no deaths reported in NMDP donor population",
      "excerpt": "\"Fewer than 1% of donors experience serious side effects from PBSC donation. The National Marrow Donor Program has facilitated more than 100,000 transplants and closely monitors donor safety.\"\n",
      "source_date": "2025-01-01",
      "source_accessed": "2026-04-18",
      "archive_url": "https://web.archive.org/web/20260420032344/https://www.nmdp.org/get-involved/join-the-registry/donate-pbsc/donor-requirements-faqs",
      "calculation_notes": "NMDP's public-facing FAQ summarizes the peer-reviewed data in accessible terms. The \"<1% serious\" figure aligns with the 0.56% from the Halter et al. prospective trial. NMDP notes no donor deaths in its registry, consistent with WMDA data reporting only one death in over 250,000 collections worldwide between 1988 and 2018.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "General anesthesia death (per procedure)",
      "lifetime_us_adult": 0.0001
    },
    {
      "label": "Serious adverse drug reaction (per prescription)",
      "lifetime_us_adult": 0.002
    },
    {
      "label": "Blood donation adverse event requiring medical attention",
      "lifetime_us_adult": 0.003
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "Bone marrow (surgical) harvest vs PBSC",
      "multiplier": 4,
      "notes": "BM donors have ~4x the SAE rate of PBSC donors (2.38% vs 0.56%)"
    },
    {
      "factor": "Female donor",
      "multiplier": 2,
      "notes": "Women are approximately twice as likely to experience an SAE compared to men"
    },
    {
      "factor": "Second-time donor",
      "multiplier": 1.2,
      "notes": "Slightly elevated risk from repeat filgrastim exposure, though long-term data show no cancer increase"
    },
    {
      "factor": "Donor age 18-30 vs 40+",
      "multiplier": 0.6,
      "notes": "NMDP and DKMS donor outcomes data: younger donors (18-30) recover faster and have lower serious adverse event rates than donors aged 40+; G-CSF mobilization side effects and post-harvest fatigue are more pronounced in older donors, and general anesthesia risk for marrow harvest scales with age"
    },
    {
      "factor": "BMI ≥ 35 or significant comorbidity",
      "multiplier": 2,
      "notes": "NMDP donor eligibility and outcomes data: donors with obesity or underlying medical conditions face higher anesthesia and mobilization risks; NMDP screens donors for these factors and may redirect to the safest collection method, but residual risk elevation persists compared to healthy-weight donors"
    }
  ],
  "short_label": "Marrow donation risk",
  "myth_framing": "overrated",
  "outcome_severity": "moderate_harm",
  "exposure_pattern": "acute",
  "outcome_type": "recoverable_injury",
  "valence": "negative",
  "caveats": "The normalized figure uses the per-donation PBSC SAE rate because most unrelated donations now use PBSC. For traditional bone marrow harvest under general anesthesia, the SAE rate is roughly four times higher (2.4%). The WMDA has documented one donor death in over 250,000 collections worldwide — a rate below 1 in 200,000. Most side effects (bone pain, fatigue, headache from G-CSF) are transient and resolve within days of collection.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 5,
    "d4": 5,
    "d5": 5,
    "d6": 5,
    "d7": 4,
    "d8": 5,
    "avg": 4.875,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "quality-review-agent",
  "last_reviewed": "2026-04-19",
  "reviewed": true,
  "generated_at": "2026-04-18",
  "image": {
    "alt": "A simplified syringe and bone cross-section rendered in muted warm tones, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/bone-marrow-donor-complications"
}